

timpanometri tipe A, namun pada penelitian ini data dari pemeriksaan DPOAE tidak dapat digunakan seluruhnya, dikarenakan hanya 16 telinga yang hasil timpanometrinya tipe A. Hal ini dikarenakan pada kasus karsinoma nasofaring hal tersebut dapat menjadi kendala. Hasil dari DPOAE pada 16 telinga didapatkan hasil yang signifikan setelah kemoterapi kedua.

C. SARAN

1. Perlu diberikan terapi tambahan berupa ginkgo biloba dengan dosis 80 mg / hari peroral pada penderita karsinoma nasofaring yang akan menjalani kemoterapi dengan cisplatin.
2. Pada penderita karsinoma nasofaring yang akan menjalani kemoterapi dengan cisplatin perlu dilakukan pemeriksaan pendengaran (dengan PTA dan DPOAE) secara berkala sebelum hingga setelah mendapatkan kemoterapi.

DAFTAR PUSTAKA

Adham M, AN K, Al M, et al. 2012 Nasopharyngeal carcinoma in Indonesia: epidemiology, incidence, signs, and symptoms at presentation. Chin J Cancer. doi:10.5732/cjc.011.10328.

- adham, M., Rohdiana,D., Mayangsari,I. D. Et Al., 2014. Delayed Diagnosis Of Nasopharyngeal Carcinoma In A Patient With Early Signs Of Unilateral Ear Disorder. *Med J Indones.* 23(1).
- Agarwala, A. K. Et Al., 2011. Salvage Chemotherapy With High-Dose Carboplatin And Etoposide With Peripheral Blood Stem Cell Transplant In Patients With Relapsed Pure Seminoma. *American Journal Of Clinical Oncology*, 34(3), Pp. 286-8.
- Alakel N, Middeke Jm, Schetelig J, Bornhauser M. 2017. Prevention And Treatment Of Tumor Lysis Syndrome, And The Efficacy And Role Of Rasburicase. *Onco Targets And Therapy.* 10:597-605. Doi: 10.2147/Ott.S103864.
- Apriliana, C., Naftali, Z. & Yusmawan, W., 2019. Penurunan Nilai Hantaran Tulang Pada Penderita Karsinoma Nasofaring Dengan Kemoterapi Berbasis Platinum: Kombinasi Neoadjuvant Paclitaxel-Cisplatin Dan Paclitaxel-Carboplatin. *Jurnal Kedokteran Diponegoro*, 8(1), pp. 80-91.
- Bachri, A. & Djufri, N.I., 2020. Retrospective Review of Nasofaring Carcinoma in Wahidin Sudirohusodo. *International Journal of Nasopharyngeal Carcinoma (IJNPC)* , 02, pp.82-84.
- Bailey B.J., et al., 2013. *Head and Neck Surgery in Otolaryngology.* 5th ed. Texas: Lippincott Williams and Wilkins. 2.
- Bánfi B, Malgrange B, Knisz J, Steger K, Dubois-Dauphin M, Krause KH, 2004. NOX3, a superoxide-generating NADPH oxidase of the inner ear. *J. Biol. Chem.* 279(44). pp. 46065–46072

- Barata R, Boesoirie T, Poerwana R. 2014 Role of Ginkgo Biloba on Sensorineural Hearing Disorders Prevention in Patients with Malignant Tumors Cisplatin therapy. *Orli*. 44 (2).pp. 96-103.
- Cakil B, Basar FS, Atmaca S, Cengel SK, Tekat A, Tanyeri Y. 2012. The protective effect of Ginkgo biloba extract against experimental cisplatin ototoxicity: animal research using distortion product otoacoustic emissions. *J Laryngo Otol*; 126(11):1097-101.
- Chan P, Xia Q, Fu Peter. 2007. Ginkgo Biloba Leave Extract: Biological, Medicinal, and Toxicological Effects. *Journal of Environmental Science and Health Part C*, 25 : 211–244.
- Chang, K.W., 2014. Ototoxicity. In: R. C. Jhonson JT, ed. *Bailey's Head and Neck Surgery-Otolaryngology. 5th ed.* Philadelphia: Lippincott Williams & Wilkins, pp. 2542-55.
- CHEN, W. & HU, G.-H. 2015. Biomarkers for enhancing the radiosensitivity of nasopharyngeal carcinoma. *Cancer Biol Med*, 12, 23-32.
- Chua DTT, 2014. Willam Ignace Wei. Nasopharyngeal Carcinoma. In: Johnson JT, Rosen CA, eds. *Bailey's Head and Neck Surgery*. Vol 5th ed. Philadelphia: Lippincot Williams & wilkins.1875-1897.
- Chua MLK, Wee JTS, Hui EP, Chan ATC (2016). Nasopharyngeal carcinoma. *Lancet*, 387, 1012-24.
- Costa RM, Chiganças V, Galhardo Rda S, Carvalho H, Menck CF. 2003. The eukaryotic nucleotide excision repair pathway. *Biochimie*. 85:1083–1099.

- Dhingra PL, 2014. Anatomy of Ear. In: Disease of Ear, Nose, and Throat, Sixth edition, Reed Elsevier India Private Limited, pp:9-14
- Esen et al. 2018. Ginkgo biloba and Lycopene are Effective on Cisplatin Induced Ototoxicity?. *J Int Adv Otol* . 14(1): 22-6 . DOI: 10.5152/iao.2017.3137
- Evans, p., et al., 2003. Chemoteraphy for Head and Neck Cancer *in: Principles and Practice of Head and Neck Oncology*. London. MartinDunitz.
- Faisal, H., 2015. Gambaran Karakteristik Karsinoma Nasofaring Dan Faktor-Faktor Yang Mempengaruhi Prognosis. *Universitas Indonesia*, pp.1-24.
- Faiza, S., Rahman, S. & Asri, A., 2016. Karakteristik Klinis dan Patologis Karsinoma Nasofaring di Bagian THT-KL RSUP Dr.M.Djamil Padang. *Jurnal Kesehatan Andalas*, 5(1), pp. 90-6.
- Firdaus, M.A., Prijadi, J., *Kemoterapi Neoadjuvan pada Karsinoma Nasofaring* (2012) Bagian Telinga Hidung Tenggorok Bedah Kepala Leher Fakultas Kedokteran Universitas Andalas/RSUP Dr. M. Djamil Padang .
- Francis V. De Feudis. 2012. Ginkgo Biloba Extract (EGb 761). From Chemistry To The Clinic. Ullstein Medical : 175-196.
- Gelfand S.A., 2016. Essentials of Audiology. 4th Ed. Thieme Medical Publishers, Inc., New York
- Guthrie OW, Li-Korotky HS, Durrant JD, Balaban C. 2008. Cisplatin induces cytoplasmic to nuclear translocation of nucleotide excision repair factors among spiral ganglion neurons. *Hear. Res.* 239:79–91.

- Hall, J.W., 2000. Handbook of Otoacoustic emissions. Jilid III. Thomson Learning. San Diego
- Hendriyanto et al., 2020. The Effect Of Ginkgo Biloba Against Ototoxic Hearing Loss On Advanced Stage Undifferentiated Nasopharyngeal Carcinoma Receiving Cisplatin Chemotherapy. *International Journal of Nasopharyngeal Carcinoma (IJNPC)*. 2(2), pp: 44-46
- James et al., 2016. Diagnostic Audiology, Hearing Instruments and Aural Habilitation. In J.B.S.J. Ashley Wackym, ed. *Ballenger's Otorhinolaryngology Head And Neck Surgery*. 18th ed. People's Medical Publishing House-USA. pp.442-93.
- Jayalie V, Paramitha M, Jessica, et al. 2016. Profile of Nasopharyngeal Carcinoma in dr. Cipto Mangunkusumo National Hospital. *E-Journal of Medicine Indonesia*.
- Jones GL, Will A, Jackson GH, Webb NJ, Rule S. 2015. British Committee for Standards in Haematology. Guideline for the management of tumor lysis syndrome in adults and children with haematological malignancies on behalf of the British Committee for Standards in Haematology. *Br J Haematol*. 169:661-71. doi: 10.1111/ bjh.13403.
- Kadir, A. ,Retnowati, K. , Akil, M.A. , Usman, A.N., 2018. The Evaluation of Serum Il-6 Changes as Proliferative Cytokines in Patients With Nasopharyngeal Carcinoma Before and After the Ionizing Radiotherapy. *Global Journal of Health Science*, 10(8), p. 55-6

- Kataki AC, Simons MJ, Das AK, et al. 2011. Nasopharyngeal carcinoma in the northeastern states of india. *Chin J Cancer*.30(1). p.106-13.
- Kentjono, W.A., 2013a. Perkembangan Terkini Penatalaksanaan Karsinoma Nasofaring. Kompilasi.
- Kentjono, W.A., 2013b. Kemoterapi Pada Karsinoma Nasofaring (Keganasan Kepala dan Leher). Majalah Pertemuan Nasional I Penatalaksanaan Karsinoma Nasofaring di Indonesia. Malang, 19 januari 2013
- Kristianti, A., Madiadipoera, T. & Soeseno, B., 2010. Pengaruh Cisplatin dosis tinggi terhadap penurunan. *ORLI*, 40(2), pp. 84-85.
- Lee JE, Nakagawa T, Kim TS, Endo T, Shiga A, Iguchi F, Lee SH, Ito J. 2004a. Role of reactive radicals in degeneration of the auditory system of mice following cisplatin treatment. *Acta Otolaryngol*.124. pp. 1131–1135.
- Lee JE, Nakagawa T, Kita T, Kim TS, Endo T, Shiga A, Iguchi F, Lee SH, Ito J. 2004b. Mechanisms of apoptosis induced by cisplatin in marginal cells in mouse striavascularis. *ORL J. Otorhinolaryngol. Relat. Spec*.66:111–118.
- Liang F, Schulte BA, Qu C, Hu W, Shen Z. 2005. Inhibition of the calcium- and voltage-dependent big conductance potassium channel ameliorates cisplatin-induced apoptosis in spiral ligament fibrocytes of the cochlea. *Neuroscience*. 135:263–271.
- Liansyah , T., 2019. Aspek Klinis dan Tatalaksana Sindrom Lisis Tumor pada Anak. *J. Ked. N. Med* , 2(1), pp.50-56.

Lin, S., HO; Willard, Fee; Francisco, Talavera. 2016. Malignant Nasopharyngeal Tumors.

<http://emedicine.medscape.com/article/848163-overview>.

[Accessed 24/4/2020].

Lo SS, Lu JJ. 2010. Natural history, presenting symptoms, and diagnosis of nasopharyngeal carcinoma. In: Brady LW, Heilmann H-P, Molls M, Nieder C, eds. *Nasopharyngeal Cancer Multidisciplinary Management*. Vol Germany: Springer. 41-52.

Mahadevan S. Park Y. 2008. Multifaceted Therapeutic Benefits of Ginkgo biloba L.: Chemistry, Efficacy, Safety, and Uses. *Journal of Food Science—Vol. 73, Nr.*

McGee, S. A. Wiggins & J. D. Pierce. 2003. What Advanced Practice Nurses Need To Know About Free Radicals . *The Internet Journal of Advanced Nursing Practice*. Volume 6 Number 1.

Melani W, Sofyan F. 2013. Karakteristik penderita kanker nasofaring di Rumah Sakit H . Adam Malik Medan tahun 2011. *E-Jurnal FK-USU*, 1(1):1-5.

Mukherjea D, Whitworth CA, Nandish S, Dunaway GA, Rybak LP, Ramkumar V. 2006. Expression of the kidney injury molecule 1 in the rat cochlea and induction by cisplatin. *Neuroscience*. 139:733–740.

Mukherjea D, Jajoo S, Whitworth C, Bunch JR, Turner JG, Rybak LP, Ramkumar V. 2008. Short interfering RNA against transient receptor

potential vanilloid 1 attenuates cisplatin-induced hearing loss in the rat. *J. Neurosci.* 28:13056–13065.

Paken, J., Govender, C., Pillay, M., & Sewram, V. 2016. Cisplatin-Associated Ototoxicity: A Review for the Health Professional. *Journal of Toxicology*, 1-13.

Paul Smith. 2004. Pharmacological Action Derived From Ginkgo Biloba. USA. ; 23 : 1-2.

Pieter, N. A. I., Yusuf; SAVITRI, E. 2013. Profil IgA(VCA-p18+EBNA1) dan Viral Load DNA EBV Sebagai Faktor Resiko Keluarga Penderita Karsinoma Nasofaring dengan EBV Positif. *Disertasi Program Doktor*. Makassar: Pasca Sarjana Universitas Hasanuddin.

Perez CA, Brady LW, Wazer DE, Halperin EC. 2013. Principles and Practice of Radiation Oncology Sixth Edition. Lippincot William. America

Punagi, A.Q., Mubarika. S., Yusuf. I. 2013. Vascular Endothelial Growth Factor Receptor (VEGFR Flt-4) and Latent Membrane Protein (LMP-1) Expression in Nasopharyngeal Carcinoma. *The Open Otorhinolaryngology Journal*, Volume 7, p. 1.

Putri EB. 2011. Karakteristik penderita karsinoma nasofaring di departemen ilmu kesehatan THT-KL FKUP/RSUP Dr. Hasan Sadikin Bandung Periode Tahun 2006 - 2010 [skripsi]. Bandung: Universitas Padjadjaran.

- Putri, M. H., Rahaju, P. & Indrasworo, D., 2017. Hubungan ototoksisitas dan kemoterapi neoadjuvan pada karsinoma nasofaring berdasarkan ASHA, CTCAE, dan DPOAE. *ORLI*, 47(2), pp. 102-12.
- Rahman, S., Alviandi, W., Edward, Y. & Firdaus, m. A., 2010. Gambaran Audiogram Nada Murni Penderita Karsinoma Kepala Dan Leher Yang Mendapat Satu Siklus Kemoterapi Cisplatin. *Majalah Kedokteran Andalas*, 34(1), pp. 51-59.
- Reavis KM, McMillan G, Austin D, Gallun F, Fausti SA, Gordon JS, et al. 2010. Distortion-product otoacoustic emission test performance for ototoxicity monitoring. *Ear and Hearing*. 32(1):61-74
- Roezin A, Adham M. 2014. Karsinoma Nasofaring. Dalam: Soepardi EA, Iskandar N, Bashirudin J, Restuti RD. Buku ajar ilmu kesehatan telinga hidung tenggorokan. Edisi ke-7. Jakarta: Badan Penerbit FKUI. hlm. 158–63.
- Rybak L, T. A. S. J., 2008. Drug-induced hearing loss. . In: J. F. R. R. Schacht, ed. *Auditory trauma, protection, and repair*. Philadelphia: springer, pp. 219-45.
- Rybak, L. P., Mukherje, D., Jajoo, S. & Ramkumar, V., 2009. Cisplatin Ototoxicity and Protection: Clinical and Experimental Studies. *Tohoku J Exp Med*, 219(3), pp. 177-186.
- Sabarin, M.S.M., Permana, A.D., Soeseno, B., 2016. Epidemiologi penderita tumor ganas kepala leher di Departemen telinga hidung tenggorok-Kepala leher rumah sakit Dr. Hasan Sadikin Bandung,

- Indonesia, periode 2010-2014. *Tunas Medika Jurnal Kedokteran dan Kesehatan*.3(1). pp 2-3.
- Santosa YI. 2012. Pengaruh Alfa Tokoferol Untuk Mencegah Efek Ototoksik Akibat Cisplatin Pada Penderita Tumor Ganas. Tesis. Ilmu Kesehatan Telinga Hidung Tenggorok-Bedah Kepala Leher, Universitas Padjadjaran.
- Shah, J., Patel, S., Singh, B. & Wong, R., 2020. *Head And Neck Surgery And Oncology*. Fifth Edition ed. London: Elsevier.
- Sheth, S., Mukherjea, D., Rybak, L. & Ramkumar, V., 2017. Mechanisms of Cysplatin-Induced Ototoxicity and Otoprotection. *Sheth S, Mukherjea D, Rybak LP and Ramkumar V (2017) Mechanisms of Cisplatin-Induced OtotoxicFront. Cell. Neurosci. 11:338. doi: 10.3389/fncel.2017.00338*.
- So H, Kim H, Lee JH, Park C, Kim Y, Kim E, Kim JK, Yun KJ, Lee KM, Lee HY, Moon SK, Lim DJ, Park R. 2007. Cisplatin cytotoxicity of auditory cells requires secretions of proinflammatory cytokines via activation of ERK and NF-kappaB. *J. Assoc. Res. Otolaryngol.* 8:338–355.
- Soetirto I, H. H. B. J., 2007. Gangguan Pedengaran dan Kelainan Telinga Dalam. In: *Buku Ajar Ilmu Kesehatan Telinga Hidung Tenggorok Kepala Leher*. Jakarta: Faakultas Kedokteran Universitas Indonesia, pp:10-20.
- Standing, Susan Et Al. 2016. *Gray's Anatomy Forty First Edition*. Elsevier, London.

- The American Joint Committee on Cancer, 2018. the 8th edition of the AJCC cancer staging manual and the future of TNM. *Annals of surgical oncology*. pp.17-19
- Tsao SW, Yip YL, Tsang CM, et al. 2014. Etiological factors of nasopharyngeal carcinoma. *Oral Oncol.* 50(5):330338. doi:10.1016/j.oraloncology.2014.02.006.
- UICC New Global Cancer Data: GLOBOCAN 2018. <https://www.uicc.org/news/new-global-cancer-data-globocan-2018>
- VanPutte, C., Regan, J., Russo, A. & Stephens, T., 2017. *Seeley's Anatomy & Physiology*. Eleventh Edition ed. New york: McGraw-Hill Education.
- Wackym, & Snow, J.B., 2016. *Ballenger's Otorhinolaryngology 18 Head And Neck Surgery*. 18th Ed. China: People's Medical Publishing House-Usa.
- Wang J, Ladrech S, Pujol R, Brabet P, Van De Water TR, Puel JL. 2004. Caspase inhibitors, but not c-Jun NH2-terminal kinase inhibitor treatment prevents cisplatininduced hearing loss. *Cancer Res.* 64:9217–9224
- Watanabe K, Inai S, Jinnouchi K, Baba S, Yagi T. 2003. Expression of caspaseactivated deoxyribonuclease (CAD) and caspase 3 (CPP32) in the cochlea of cisplatin (CDDP)-treated guinea pigs. *Auris Nasus Larynx*.30:219–225.
- Wei, G. J., Zenghung, LI; Wai, Kueen, HO; Jimmy, Yuwai, Chan; Thian, Sze, Wong, 2012. Biomarkers for Use in Monitoring Responses of

Nasopharyngeal Carcinoma Cells to Ionizing Radiation. *Sensors*, 12:8832-8846.

Wildeman MA, Fles R, Herdini C, Indrasari RS, Vincent AD, Tjokronagoro M, et al. 2013. Primary treatment results of Nasopharyngeal Carcinoma (NPC) in Yogyakarta, Indonesia. *PLoS One*. 8(5).

Witte M.C, Neel, 2010 . Nasopharyngeal Cancer. In: Byron J.Bailey, editors. Head and neck otolaryngology, 5th ed. Lippincot-Raven.Philadelphia 2013 : p.1637-1653.

Zhang M, Liu W, Ding D, Salvi R. 2003. Pifithrin-alpha suppresses p53 and protects cochlear and vestibular hair cells from cisplatin induced apoptosis. *Neuroscience*. 120:191–205.

LAMPIRAN

Lampiran 1.

Lembar informed consent

Lembar Penjelasan Penelitian

Nama Peneliti : Martina Martha Tilova

NIM : C035171003

Alamat : Dyandara Residence Blok A No. 5, wesabbe,
Tamalanrea, Makassar, Sulawesi Selatan

Judul Penelitian : Pengaruh Ginkgo Biloba Terhadap Ambang
Pendengaran dan Fungsi Sel Rambut Luar Koklea
Penderita Karsinoma Nasofaring Dengan Terapi
Cisplatin Dan Paclitaxel.

Peneliti adalah mahasiswa Program Pendidikan Dokter Spesialis-1 Fakultas Kedokteran Universitas Hasanuddin Makassar. Saudara telah diminta ikut berpartisipasi dalam penelitian ini. Responden dalam penelitian ini adalah secara sukarela. Saudara berhak menolak berpartisipasi dalam penelitian ini. Penelitian ini dilakukan dengan cara melihat rekam medis saudara, melakukan pemeriksaan ambang pendengaran dan fungsi sel rambut luar sebelum kemoterapi dan setelah kemoterapi dengan regimen Cisplatin dan Paclitaxel. Segala informasi yang saudara berikan dan data rekam medis saudara akan digunakan sepenuhnya hanya dalam penelitian ini. Peneliti sepenuhnya akan menjaga kerahasiaan identitas dan isi rekam

medis saudara serta tidak dipublikasikan dalam bentuk apapun. Jika ada yang belum jelas, saudara boleh bertanya pada peneliti. Jika saudara sudah memahami penjelasan ini dan bersedia berpartisipasi dalam penelitian ini, silahkan saudara menandatangani lembar persetujuan yang akan dilampirkan.

Peneliti

Martina Martha Tilova

Lembar Persetujuan Responden (Informed Consent)

Saya yang bertanda tangan dibawah ini :

Nama :

Umur :

Alamat :

Menyatakan bersedia menjadi responden pada penelitian yang di lakukan oleh :

Nama Peneliti : Martina Martha Tilova

NIM : C035171003

Alamat : Dyandara Residence Blok A No. 5, wesabbe,
Tamalanrea, Makassar, Sulawesi Selatan

Judul Penelitian : Pengaruh Ginkgo Biloba Terhadap Ambang
Pendengaran dan Fungsi Sel Rambut Luar Koklea
Penderita Karsinoma Nasofaring Dengan Terapi
Cisplatin Dan Paclitaxel.

Saya bersedia untuk dilakukan pemeriksaan dan memberikan ijin peneliti untuk melihat rekam medis saya, demi kepentingan penelitian. Dengan ketentuan, hasil pemeriksaan dan isi rekam medis saya akan dirahasiakan dan digunakan hanya semata-mata untuk kepentingan ilmu pengetahuan. Demikian surat pernyataan ini saya sampaikan, agar dapat dipergunakan sebagaimana mestinya.

Makassar,.....2020

Responden

(.....)

Lampiran 2

**KARTU KONTROL PENGGUNAAN OBAT
Ginkgo Biloba 80 mg/24 jam/oral/hari**

Nomor Sampel Penelitian :
Tanggal Mulai Terapi :
Rumah Sakit :
Nomor Rekam Medis :
Nama :
Jenis Kelamin :

Hari ke-	Tanggal	Jam (WITA)
1		
2		
3		
4		
5		
6		
7		
8		
9		
10		
11		
12		
13		
14		
15		
16		
17		
18		

19		
20		
21		
22		
23		
24		
25		
26		
27		
28		
29		
30		

Lampiran 3. Data Dasar Penelitian

DATA PRIMER PEMERIKSAAN PTA TELINGA KANAN PENDERITA KNF SEBELUM KEMOTERAPI CISPLATIN- PACLITAXEL (DENGAN TERAPI GINKGO BILOBA)

N O	Nama	JK	Umur	Diagnosa	Frekuensi						D/	Timpanogram	
					AC/B C	0, 5	1	2	4	6			8
1	AT	L	45	KNF stadium III	AC	40	55	85	85	80	80	MHL sedang berat (65 dB)	Tipe C
					BC	15	30	65	60	55↓	50↓		
2	EM	P	30	KNF stadium IV A	AC	35	35	40	45	55	60	CHL ringan (38,75 dB)	Tipe As
					BC	0	0	5	15	20	25		
3	N	L	36	KNF stadium III	AC	45	40	40	45	50	55	CHL sedang (42,5 dB)	Tipe B
					BC	- 10	-10	0	0	15	10		
4	IY	L	40	KNF stadium III	AC	25	30	25	35	50	60	CHL RINGAN (28,75 dB)	Tipe B
					BC	5	5	10	20	25	25		
5	BN	P	33	KNF stadium IVB	AC	25	35	35	25	30	35	CHL ringan (30 dB)	Tipe A
					BC	0	5	15	10	15	15		
6	J	L	45	KNF stadium II	AC	10	10	10	15	35	25	NH (11.25 dB)	Tipe A
					BC	5	5	5	10	15	20		

7	S	P	51	KNF stadium III	AC	80	85	80	70	75	80	MHL berat (78,75 dB)	Tipe B
					BC	25	35	30	25	40	30		
8	AD	L	43	KNF stadium III	AC	30	35	25	45	45	40	CHL ringan (33,75 dB)	Tipe As
					BC	5	5	5	15	15	10		
9	M	L	51	KNF stadium IVA	AC	40	50	50	80	95	95	MHL sedang (55dB)	Tipe As
					BC	15	20	30	45	45	45		

**DATA PRIMER PEMERIKSAAN PTA TELINGA KANAN PENDERITA KNF SETELAH KEMOTERAPI PERTAMA
KEMOTERAPI CISPLATIN-PACLITAXEL (DENGAN TERAPI GINKGO BILOBA)**

N O	Nama	JK	Umur	Diagnosa	Frekuensi							D/	Timpanogram
					AC/B C	0,5	1	2	4	6	8		
1	AT	L	45	KNF stadium III	AC	55	70	80	95	90	85	MHL berat (75 dB)	Tipe B
					BC	20	30	65	60	55↓	50c		
2	EM	P	30	KNF stadium IV A	AC	25	25	35	55	90	90	CHL ringan (30dB)	Tipe As
					BC	5	5	5	35	35	45		
3	N	L	36	KNF stadium III	AC	5	10	10	10	35	35	NH (8,75 dB)	Tipe A
					BC	-10	-5	0	5	15	15		
4	IY	L	40	KNF stadium III	AC	40	45	45	65	70	85	CHL sedang (48,75 dB)	Tipe B
					BC	5	5	10	20	25	30		

5	BN	P	33	KNF stadium IVB	AC	25	50	40	35	35	45	CHL ringan (37,5 dB)	Tipe A
					BC	0	5	15	10	15	20		
6	J	L	45	KNF stadium II	AC	10	10	10	20	20	25	NH (12,5 dB)	Tipe A
					BC	5	5	5	15	15	25		
7	S	P	51	KNF stadium III	AC	75	85	75	80	90	90↓	MHL berat (78.75dB)	Tipe B
					BC	30	35	30	35	45	50↓		
8	AD	L	43	KNF stadium III	AC	25	10	15	35	45	50	NH (21,25 dB)	Tipe As
					BC	5	5	5	15	20	25		
9	M	L	51	KNF stadium IVA	AC	40	50	70	100	100↓	90↓	MHL sedang berat (65 dB)	Tipe As
					BC	15	20	30	60	50	50↓		

DATA PRIMER PEMERIKSAAN PTA TELINGA KANAN PENDERITA KNF SETELAH KEMOTERAPI KEDUA KEMOTERAPI CISPLATIN-PACLITAXEL (DENGAN TERAPI GINKGO BILOBA)

DATA PRIMER PEMERIKSAAN PTA TELINGA KIRI PENDERITA KNF SEBELUM KEMOTERAPI CISPLATIN-PACLITAXEL (DENGAN TERAPI GINKGO BILOBA)

NO	Nama	JK	Umu r	Diagnosa	Frekuensi							D/	Timpanogram
					AC/B C	0, 5	1	2	4	6	8		
1	AT	L	45	KNF stadium III	AC	45	80	70	60	65	70	MHL sedang berat (63,75 dB)	Tipe A

					BC	30	70	70	60	55↓	50↓		
2	EM	P	30	KNF stadium IV A	AC	30	35	35	60	85	90	CHL ringan (40dB)	Tipe As
					BC	5	5	5	30	40	45		
3	N	L	36	KNF stadium III	AC	10	5	5	10	30	30	NH (7,5 dB)	Tipe A
					BC	-5	0	0	5	15	15		
4	IY	L	40	KNF stadium III	AC	10	10	10	25	40	50	NH (13,75 dB)	Tipe A
					BC	5	5	10	20	25	30		
5	BN	P	33	KNF stadium IVB	AC	15	15	15	15	20	25	NH (11,25 dB)	Tipe A
					BC	15	5	15	10	15	20		
6	J	L	45	KNF stadium II	AC	5	5	5	20	25	50	NH (8,75 dB)	Tipe A
					BC	5	5	5	15	15	35		
7	S	P	51	KNF stadium III	AC	70	90	65	75	85	90↓	MHL berat (75 dB)	Tipe B
					BC	35	40	30	35	45	50↓		
8	AD	L	43	KNF stadium III	AC	25	20	15	30	45	55	NH (22,5 dB)	Tipe As
					BC	5	10	5	15	20	25		
9	M	L	51	KNF stadium IV A	AC	40	45	75	100	100↓	90↓	MHL sedang berat (65 dB)	Tipe As
					BC	20	20	30	60	50	50↓		
	NO	Nama	JK	Umu r	Diagnosa	Frekuensi						DIAGNOSA	Timpanogram

					AC/B C	0, 5	1	2	4	6	8		
1	AT	L	45	KNF stadium III	AC	70	90	70	11 0	100	90	MHL berat (82,5 dB)	Tipe C
					BC	25	35	55	65	55↓	50↓		
2	EM	P	30	KNF stadium IV A	AC	5	5	5	5	15	10	NH (7, 5 dB)	Tipe As
					BC	0	-5	0	-5	0	0		
3	N	L	36	KNF stadium III	AC	10	10	10	10	20	15	NH (10 dB)	Tipe A
					BC	-5	-10	-5	-10	0	0		
4	IY	L	40	KNF stadium III	AC	5	5	10	5	25	20	NH (6, 25 dB)	Tipe A
					BC	-5	0	5	0	10	10		
5	BN	P	33	KNF stadium IVB	AC	35	20	20	20	30	40	NH (23,75 dB)	Tipe A
					BC	0	5	15	10	15	20		
6	J	L	45	KNF stadium II	AC	30	40	35	75	80	55	CHL sedang (46,75dB)	Tipe B
					BC	10	10	15	40	30	30		
7	S	P	51	KNF stadium III	AC	45	50	45	35	45	55	CHL sedang(43,75 dB)	Tipe B
					BC	25	25	20	15	25	30		

8	AD	L	43	KNF stadium III	AC	30	30	30	40	40	35	CHL ringan (30,25 dB)	Tipe A
					BC	10	10	10	10	15	10		
9	M	L	51	KNF stadium IVA	AC	25	30	30	45	90	90	CHL ringan 32,5 dB)	Tipe A
					BC	10	15	15	20	40	45		

**DATA PRIMER PEMERIKSAAN PTA TELINGA KIRI PENDERITA KNF SETELAH KEMOTERAPI PERTAMA
KEMOTERAPI CISPLATIN-PACLITAXEL (DENGAN TERAPI GINKGO BILOBA)**

N O	Nama	JK	Umur	Diagnosa	Frekuensi							D/	Timpanogram
					AC/B C	0,5	1	2	4	6	8		
1	AT	L	45	KNF stadium III	AC	70	85	100	115	105	100	MHL profound (92,5 dB)	Tipe B—setelah diterapi menjadi tipe A
					BC	25	35	60	65	55↓	50↓		
2	EM	P	30	KNF stadium IVA	AC	5	10	5	10	40	50	NH (5 dB)	Tipe As
					BC	0	0	0	5	25	35		
3	N	L	36	KNF stadium III	AC	10	10	15	10	30	30	NH (11,25 dB)	Tipe A
					BC	-5	-5	-5	0	5	10		
4	IY	L	40	KNF stadium III	AC	20	10	15	55	45	55	NH (25 dB)	Tipe A
					BC	5	0	5	30	25	25		

5	BN	P	33	KNF stadium IVB	AC	30	25	20	20	25	40	NH (23,75 dB)	Tipe A
					BC	0	5	15	10	15	20		
6	J	L	45	KNF stadium II	AC	10	10	20	75	65	70	CHL ringan (30 dB)	Tipe As → setelah diterapi tipe A
					BC	10	10	15	45	30	30		
7	S	P	51	KNF stadium III	AC	40	40	35	35	65	75	CHL ringan (37,5 dB)	Tipe B
					BC	25	25	20	15	25	30		
8	AD	L	43	KNF stadium III	AC	20	25	25	35	45	50	CHL ringan (26,25 dB)	Tipe A
					BC	10	15	10	15	20	20		
9	M	L	51	KNF stadium IVA	AC	20	20	30	50	100↓	90↓	CHL ringan (30 dB)	Tipe A
					BC	10	15	25	25	50	50↓		

DATA PRIMER PEMERIKSAAN PTA TELINGA KIRI PENDERITA KNF SETELAH KEMOTERAPI KEDUA
KEMOTERAPI CISPLATIN-PACLITAXEL (DENGAN TERAPI GINKGO BILOBA)

NO	Nama	JK	Umur	Diagnosa	Frekuensi						D/	Timpanogram	
					AC/BC	0,5	1	2	4	6			8
1	AT	L	45	KNF stadium III	AC	25	40	75	70	80	85	SNHL sedang (52,5 dB)	Tipe A
					BC	25	40	65	70	55↓	50↓		
2	EM	P	30	KNF stadium IV A	AC	5	5	5	5	35	40	NH (7,5 dB)	Tipe As

3	N	L	36	KNF stadium III	BC	0	0	0	5	35	35	NH (17,5 dB)	Tioe A
					AC	15	15	20	20	30	35		
4	IY	L	40	KNF stadium III	BC	5	-5	0	5	5	15	NH (22,5 dB)	Tipe A
					AC	15	10	15	55	50	60		
5	BN	P	33	KNF stadium IVB	BC	5	5	5	30	25	35	NH (25 dB)	Tipe A
					AC	25	20	25	30	35	45		
6	J	L	45	KNF stadium II	BC	15	10	15	25	15	25	NH (22,5 dB)	Tipe A
					AC	5	15	20	50	70	65		
7	S	P	51	KNF stadium III	BC	10	10	15	45	35	35	CHL ringan (28,75 dB)	Tipe B
					AC	30	35	25	25	65	90		
8	AD	L	43	KNF stadium III	BC	25	25	20	20	30	40	CHL ringan (28,75 dB)	Tipe A
					AC	20	25	20	40	45	55		
9	M	L	51	KNF stadium IV A	BC	10	15	15	20	20	25	CHL sedang (50 dB)	Tipe A
					AC	45	50	50	55	100	90↓		
					BC	20	20	25	25	50	50↓		

DATA PRIMER PEMERIKSAAN PTA TELINGA KANAN PENDERITA KNF SEBELUM KEMOTERAPI CISPLATIN-PACLITAXEL (TANPA TERAPI GINKGO BILOBA)

NO	Nama	J K	Umu r	Diagnosa	Frekuensi	DIAGNOSA	Timpanogram
----	------	--------	----------	----------	-----------	----------	-------------

					AC/B C	0, 5	1	2	4	6	8		
1	S	L	33	KNF stadium III	AC	25	25	10	5	5	5	NH(16,25 dB)	Tipe A
					BC	10	10	10	5	0	0		
2	R	P	32	KNF stadium IV A	AC	40	35	45	55	45	50	CHL sedang (43,75 dB)	Tipe As
					BC	5	5	10	10	5	15		
3	A	L	44	KNF stadium II	AC	5	5	10	10	20	10	NH(7,5 dB)	Tipe A
					BC	0	0	0	5	10	5		
4	BD	L	43	KNF stadium IV B	AC	40	25	25	15	15	20	CHL ringan (26,25 dB)	Tipe A
					BC	15	15	25	15	10	10		
5	IB	L	20	KNF stadium IVB	AC	40	30	20	25	20	20	CHL ringan (28,75 dB)	Tipe A
					BC	10	10	10	5	10	10		
6	E	L	27	KNF stadium IVA	AC	50	55	50	50	45	45	CHL sedang (51,25 dB)	Tipe B
					BC	10	10	15	15	10	10		
7	MA	L	33	KNF stadium IVA	AC	35	30	30	35	35	25	CHL ringan (32,5 dB)	Tipe A
					BC	15	10	15	15	20	20		
8	M	P	36	KNF stadium IVA	AC	10	5	5	10	15	5	NH (7,5 dB)	Tipe As
					BC	5	5	5	10	10	5		
9	AS	L	29	KNF stadium IVA	AC	10	10	15	55	75	60	NH (25 dB)	Tipe A

					BC	-5	0	-5	25	30	45		
--	--	--	--	--	----	----	---	----	----	----	----	--	--

**DATA PRIMER PEMERIKSAAN PTA TELINGA KANAN PENDERITA KNF SETELAH KEMOTERAPI PERTAMA
CISPLATIN-PACLITAXEL (TANPA TERAPI GINKGO BILOBA)**

NO	Nama	JK	Umur	Diagnosa	Frekuensi							D/	Timpanogram
					AC/B C	0,5	1	2	4	6	8		
1	S	L	33	KNF stadium III	AC	35	30	20	25	20	20	CHL ringan (27,25 dB)	Tipe A
					BC	10	15	20	25	15	10		
2	R	P	32	KNF stadium IVA	AC	30	35	30	45	55	60	CHL ringan (35 dB)	Tipe As
					BC	5	10	10	15	20	20		
3	A	L	44	KNF stadium II	AC	0	0	10	10	25	15	NH (5 dB)	Tipe A
					BC	5	5	0	5	10	10		
4	BD	L	43	KNF stadium IV B	AC	40	30	25	45	45	65	MHL ringan (35 dB)	Tipe A
					BC	30	20	25	30	30	40		
5	IB	L	20	KNF stadium IVB	AC	30	15	15	5	15	10	NH (16,25 dB)	Tipe A
					BC	25	10	10	5	10	10		
6	E	L	27	KNF stadium IV A	AC	45	40	50	40	45	55	CHL sedang (43,75 dB)	Tipe C
					BC	10	15	30	30	30	25		
7	MA	L	33	KNF stadium IVA	AC	30	25	30	45	40	40	CHL ringan (32,5 dB)	Tipe A
					BC	15	10	20	20	25	30		

8	M	P	36	KNF stadium IVA	AC	10	10	15	20	25	25	NH (13,75 dB)	Tipe As
					BC	5	5	10	10	15	15		
9	AS	L	29	KNF stadium IVA	AC	15	10	15	50	60	70	NH (22,5 dB)	Tipe A
					BC	5	0	5	25	30	50		

DATA PRIMER PEMERIKSAAN PTA TELINGA KANAN PENDERITA KNF KEMOTERAPI SETELAH KEMOTERAPI
KEDUA CISPLATIN-
PACLITAXEL (TANPA TERAPI GINKGO BILOBA)

DATA PRIMER PEMERIKSAAN PTA TELINGA KIRI PENDERITA KNF SEBELUM KEMOTERAPI CISPLATIN-
PACLITAXEL (TANPA TERAPI GINKGO BILOBA)

NO	Nama	JK	Umur	Diagnosa	Frekuensi							D/	Timpanogram
					AC/BC	0,5	1	2	4	6	8		
1	S	L	33	KNF stadium III	AC	60	50	60	55	70	80	MHL sedang Berat (56,25dB)	Tipe A
					BC	25	35	50	45	50	50↓		
2	R	P	32	KNF stadium IV A	AC	35	30	25	55	50	45	CHL ringan (36,75 dB)	Tipe As
					BC	10	10	15	20	20	25		
3	A	L	44	KNF stadium II	AC	10	5	5	25	20	15	NH(11,25 dB)	Tipe A

					BC	5	5	5	25	15	15		
4	BD	L	43	KNF stadium IV B	AC	30	20	25	30	35	50	SNHL ringan (26,25dB)	Tipe A
					BC	30	20	25	30	30	40		
5	IB	L	20	KNF stadium IV B	AC	30	20	20	30	35	40	SNHL ringan (26, 25 dB)	Tipe A
					BC	25	15	15	20	25	25		
6	E	L	27	KNF stadium IV A	AC	35	25	35	45	55	65	MHL ringan (35 dB)	Tipe C
					BC	10	15	30	35	35	40		
7	MA	L	33	KNF stadium IVA	AC	20	25	35	55	50	55	MHL ringan (31,25 dB)	Tipe A
					BC	15	10	30	45	35	30		
8	M	P	36	KNF stadium IVA	AC	15	15	25	30	35	40	NH (21, 25dB)	Tipe As
					BC	5	5	15	15	15	20		
9	AS	L	29	KNF stadium IVA	AC	25	20	25	30	40	60	NH (25 dB)	Tipe A
					BC	10	5	15	25	35	50		
N O	Nama	JK	Umur	Diagnosa	Frekuensi						D/	Timpanogram	
					AC/BC	0,5	1	2	4	6			8
1	S	L	33	KNF stadium III	AC	35	30	35	45	45	60	CH ringan (36,25 dB)	Tipe C
					BC	10	15	20	15	10	20		
2	R	P	32	KNF stadium IVA	AC	5	15	10	5	20	15	NH (8.75 dB)	Tipe A

3	A	L	44	KNF stadium II	BC	-10	0	-5	-5	0	0	CHL ringan (40dB)	Tipe B
					AC	35	40	40	45	45	25		
4	BD	L	43	KNF stadium IV B	BC	0	0	0	10	10	0	NH (18,75 Db)	Tipe A
					AC	25	20	15	15	10	20		
5	IB	L	20	KNF stadium IV B	BC	15	15	15	15	10	10	CHL ringan (33,75 dB)	Tipe As
					AC	40	35	25	35	35	50		
6	E	L	27	KNF stadium IV A	AC	15	20	20	20	15	15	NH (18,75 dB)	Tipe A
					BC	10	15	15	10	10	10		
7	MA	L	33	KNF stadium IVA	AC	40	35	30	35	55	35	CHL ringan (35 dB)	Tipe A
					BC	10	15	20	20	20	20		
8	M	P	36	KNF stadium IVA	AC	30	25	25	35	65	60	CHL ringan (28,75 dB)	Tipe As
					BC	5	5	5	25	10	15		
9	AS	L	29	KNF stadium IVA	AC	5	5	5	15	45	40	NH (7,5 dB)	Tipe As
					BC	0	0	-5	5	45	40		

DATA PRIMER PEMERIKSAAN PTA TELINGA KIRI PENDERITA KNF SETELAH KEMOTERAPI PERTAMA
CISPLATIN-PACLITAXEL (TANPA TERAPI GINKGO BILOBA)

DATA PRIMER PEMERIKSAAN PTA TELINGA KIRI PENDERITA KNF SETELAH KEMOTERAPI KEDUA CISPLATIN-
PACLITAXEL (TANPA TERAPI GINKGO BILOBA)

N O	Nama	JK	Umur	Diagnosa	Frekuensi							DIAGNOSA	Timpanogram
					AC/B C	0,5	1	2	4	6	8		
1	S	L	33	KNF stadium III	AC	40	35	40	35	50	60	MHL mild (37,5 dB)	Tipe C
					BC	15	20	30	30	35	35		
2	R	P	32	KNF stadium IVA	AC	5	10	5	5	25	30	NH (6,25 dB)	Tipe A
					BC	-5	5	0	0	5	10		
3	A	L	44	KNF stadium II	AC	35	40	40	40	40	30	CHL ringan (38,75dB)	Tipe B
					BC	5	0	0	15	10	0		
4	BD	L	43	KNF stadium IV B	AC	30	20	15	30	35	50	NH (23,75 dB)	Tipe A
					BC	30	20	15	20	25	30		
5	IB	L	20	KNF stadium IV B	AC	35	20	20	30	35	40	CH ringan (26,25 dB)	Tipe C
					BC	15	15	15	25	25	25		
6	E	L	27	KNF stadium IV A	AC	20	20	20	25	30	35	NH (21,25 dB)	Tipe A
					BC	10	15	15	20	15	20		
7	MA	L	33	KNF stadium IVA	AC	30	20	30	45	50	50	MHL ringan (31,25 dB)	Tipe A
					BC	10	15	30	35	40	35		

8	M	P	36	KNF stadium IVA	AC	30	20	25	35	65	65	CHL ringan (27,5 dB)	Tipe As
					BC	5	5	10	25	20	20		
9	AS	L	29	KNF stadium IVA	AC	10	30	25	35	60	65	NH (25 dB)	Tipe As
					BC	5	5	0	15	50	45		
N O	Nama	JK	Umur	Diagnosa	Frekuensi							D/	Timpanogram
					AC/B C	0,5	1	2	4	6	8		
1	S	L	33	KNF stadium III	AC	40	3 5	40	40	50	50	MH ringan (38,75dB)	Tipe C
					BC	20	2 5	30	35	40	45		
2	R	P	32	KNF stadium IVA	AC	5	5	5	15	20	20	NH (7,5 dB)	Tipe As
					BC	0	5	0	10	5	15		
3	A	L	44	KNF stadium II	AC	25	3 0	35	40	45	45	CH (32,5 dB)	Tipe B
					BC	5	5	5	25	15	5		
4	BD	L	43	KNF stadium IV B	AC	30	2 0	15	25	35	40	NH (22,5 dB)	Tipe A
					BC	30	2 0	15	25	25	30		
5	IB	L	20	KNF stadium IV B	AC	40	4 0	30	40	45	55	MHL ringan (37,5 dB)	Tipe C
					BC	20	2 5	30	30	40	45		

6	E	L	27	KNF stadium IV A	AC	15	1 5	40	45	45	50	MHL ringan (28,75 dB)	Tipe A
					BC	15	1 5	30	25	30	35		
7	MA	L	33	KNF stadium IVA	AC	25	2 0	35	55	60	55	MHL ringan (33,75 dB)	Tipe A
					BC	10	1 5	30	35	45	40		
8	M	P	36	KNF stadium IVA	AC	30	2 0	25	35	40	45	CHL ringan (27,5 dB)	Tipe As
					BC	5	1 0	10	25	20	25		
9	AS	L	29	KNF stadium IVA	AC	20	2 5	40	40	65	75	MHL ringan (31,25 dB)	Tipe As
					BC	5	5	30	30	55	50↓		

DATA PRIMER PEMERIKSAAN OAE PENDERITA KNF SEBELUM
KEMOTERAPI CISPLATIN-PACLITAXEL (DENGAN TERAPI GINKGO
BILOBA)

No	Nama	Kanan	Kiri
1	AT	Pass	Refer
2	EM	Pass	Pass
3	N	Refer	Pass
4	IY	Refer	Pass
5	BN	Pass	Pass
6	J	Pass	Refer
7	S	Refer	Refer
8	AD	Pass	Pass
9	M	Pass	Pass

DATA PRIMER PEMERIKSAAN OAE PENDERITA KNF SETELAH
KEMOTERAPI PERTAMA CISPLATIN-PACLITAXEL (DENGAN TERAPI
GINKGO BILOBA)

No	Nama	Kanan	Kiri
1	AT	Pass	Refer
2	EM	Refer	Refer
3	N	Pass	Pass
4	IY	Refer	Refer
5	BN	Pass	Pass
6	J	Pass	Pass
7	S	Refer	Refer
8	AD	Pass	Pass
9	M	Pass	Pass

DATA PRIMER PEMERIKSAAN OAE PENDERITA KNF SETELAH
KEMOTERAPI KEDUA CISPLATIN-PACLITAXEL (DENGAN TERAPI
GINKGO BILOBA)

No	Nama	Kanan	Kiri
1	AT	Refer	Pass
2	EM	Refer	Refer
3	N	Pass	Pass
4	IY	Pass	Refer
5	BN	Pass	Pass
6	J	Pass	Pass
7	S	Refer	Refer
8	AD	Pass	Pass
9	M	Pass	Pass

DATA PRIMER PEMERIKSAAN OAE PENDERITA KNF SEBELUM
KEMOTERAPI CISPLATIN-PACLITAXEL (TANPA TERAPI GINKGO
BILOBA)

No	Nama	Kanan	Kiri
1	S	Pass	Refer
2	R	Pass	Pass
3	A	Pass	Refer
4	BD	Pass	Pass
5	IB	Pass	Refer
6	E	Refer	Pass
7	MA	Pass	Pass
8	M	Pass	Pass
9	AS	Pass	Pass

DATA PRIMER PEMERIKSAAN OAE PENDERITA KNF SETELAH
KEMOTERAPI PERTAMA CISPLATIN-PACLITAXEL (TANPA TERAPI
GINKGO BILOBA)

No	Nama	Kanan	Kiri
1	S	Refer	Refer
2	R	Pass	Pass
3	A	Pass	Refer
4	BD	Refer	Refer
5	IB	Pass	Refer
6	E	Refer	Pass
7	MA	Pass	Refer
8	M	Pass	Pass
9	AS	Pass	Pass

DATA PRIMER PEMERIKSAAN OAE PENDERITA KNF SETELAH KEMOTERAPI KEDUA CISPLATIN-PACLITAXEL
(TANPA TERAPI GINKGO BILOBA)

No	Nama	Kanan	Kiri
1	S	Refer	Refer
2	R	Pass	Pass
3	A	Pass	Refer
4	BD	Refer	Refer
5	IB	Refer	Refer
6	E	Refer	Refer
7	MA	Refer	Refer
8	M	Pass	Pass
9	AS	Pass	Refer

HASIL TIMPANOMETRI SEBELUM KEMOTERAPI (DENGAN GINKGO BILOBA)

No	Nama	Kanan	Kiri
1	AT	TIPE C	TIPE C
2	EM	TIPE As	TIPE As
3	N	TIPE B	TIPE A
4	IY	TIPE B	TIPE As
5	BN	TIPE A	TIPE A
6	J	TIPE A	TIPE B
7	S	TIPE B	TIPE B
8	AD	TIPE As	TIPE A
9	M	TIPE As	TIPE A

HASIL TIMPANOMETRI SEBELUM KEMOTERAPI (TANPA GINKGO BILOBA)

No	Nama	Kanan	Kiri
1	S	TIPE A	TIPE C
2	R	TIPE As	TIPE A
3	A	TIPE A	TIPE B
4	BD	TIPE A	TIPE A
5	IB	TIPE A	TIPE C
6	E	TIPE B	TIPE A
7	MA	TIPE A	TIPE A
8	M	TIPE As	TIPE As
9	AS	TIPE A	TIPE As

Lampiran 4. Rekomendasi Persetujuan Etik



REKOMENDASI PERSETUJUAN ETIK

Nomor : 414/UN4.6.4.5.31/ PP36/ 2021

Tanggal: 25 Juni 2021

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH21040237	No Sponsor Protokol	
Peneliti Utama	dr. Martina Martha Tilova	Sponsor	
Judul Peneliti	PENGARUH GINKGO BILOBA TERHADAP AMBANG PENDENGARAN DAN FUNGSI SEL RAMBUT LUAR KOKLEA PENDERITA KARSINOMA NASOFARING DENGAN TERAPI CISPLATIN DAN PACLITAXEL.		
No Versi Protokol	2	Tanggal Versi	23 Juni 2021
No Versi PSP	2	Tanggal Versi	23 Juni 2021
Tempat Penelitian	RS Universitas Hasanuddin dan RS Dr. Wahidin Sudirohusodo Makassar		
Jenis Review	<input type="checkbox"/> Exempted <input type="checkbox"/> Expedited <input checked="" type="checkbox"/> Fullboard Tanggal 5 Mei 2021	Masa Berlaku 25 Juni 2021 sampai 25 Juni 2022	Frekuensi review lanjutan
Ketua Komisi Etik Penelitian Kesehatan FKUH	Nama Prof.Dr.dr. Suryani As'ad, M.Sc.,Sp.GK (K)	Tanda tangan	
Sekretaris Komisi Etik Penelitian Kesehatan FKUH	Nama dr. Agussalim Bukhari, M.Med.,Ph.D.,Sp.GK (K)	Tanda tangan	

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Laporan SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari prokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan

Lampiran 5. Dokumentasi Penelitian




Pemeriksaan PTA (Air Conduction)



Pemeriksaan PTA (Bone Conduction)



Alat DPOAE



Alat PTA